Bronchiectasis with infection
Conditions
Interventions
Control group A :Bronchoalveolar lavage, 90ml injection group
Study group B :Bronchoalveolar lavage, 180ml injection group
Sponsors
Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=18 years old; 2. Chest CT showed bronchiectasis; 3. Patients with symptoms such as cough, sputum production, chest tightness or wheezing, and agree to bronchoscopy and bronchoalveolar lavage; 4. Patients with BSI score of moderate to severe bronchiectasis; 5. Informed consent to participate in this clinical study and sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1. Contraindications to bronchoscopy such as severe cardiopulmonary diseases, coagulation dysfunction, anesthesia intolerance, psychiatric diseases or severe neuroses; 2. Unable to cooperate with the study for any reason or the investigator believes that it is not suitable to be included in the study for other reasons; 3. Under bronchoscopy, the patient has obvious intra-airway bleeding and may be at risk of aggravation due to bronchoalveolar lavage;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom improvement (cough, phlegm, chest tightness, wheezing, hemoptysis, etc.) in both groups after treatment;Length of time from treatment to recurrence of acute exacerbations in both groups (days);Frequency of acute exacerbations one year after treatment in both groups; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of blood examination inflammatory indicators (WBC, N%, CRP, PCT, etc.) in the two groups after treatment;Absorption of chest CT lesion (exudation area of lung inflammation) in two groups after treatment;The occurrence of adverse reactions (chest tightness, shortness of breath, increased respiratory failure, increased hemoptysis, new pneumonia lesions or obvious signs of new infection, which were considered to be related to lavage treatment) in the two groups after treatment; | — |
Countries
China
Contacts
Public ContactZhongbo Chen
Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Outcome results
None listed